The Finnish Diabetes Risk Score (FINDRISC), incident diabetes and low-grade inflammation.


Journal

Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 25 09 2020
revised: 02 11 2020
accepted: 11 11 2020
pubmed: 27 11 2020
medline: 16 3 2021
entrez: 26 11 2020
Statut: ppublish

Résumé

The FINDRISC was created to predict the development of type 2 diabetes mellitus (T2DM). Since T2DM associates with inflammation we evaluated if the FINDRISC could predict either current or incident T2DM, and elevated high sensitivity C-reactive protein (hs-CRP). 41,880 people (age 41.9 ± 9.7 years; 31% female) evaluated between 2008 and 2016 were included. First, the cross-sectional association between the FINDRISC with presence of either T2DM or hs-CRP ≥ 2.0 mg/L was tested. After a 5 ± 3 years follow-up we tested the score predictive value for incident T2DM and inflammation in respectively 10,559 individuals without diabetes and in a subset of 2,816 individuals having no elevated hs-CRP at baseline. In the cross sectional analysis the FINDRISC was associated with both T2DM (OR 1.24, 95% CI: 1.23-1.26, P < 0.001) and inflammation (OR 1.10, 95% CI: 1.09-1.11, P < 0.001) per FINDRISC unit, as well as in longitudinal analyses (OR 1.17, 95% CI: 1.14-1.20, P < 0.001; and OR 1.04, 95% CI: 1.02-1.07, P < 0.001; respectively, per FINDRISC unit). The C-statistic for incident T2DM and inflammation was 0.79 (95% CI 0.77-0.82) and 0.55 (95% CI 0.53-0.58), respectively. The FINDRISC shows good discrimination for incident T2DM but less for inflammation.

Identifiants

pubmed: 33242513
pii: S0168-8227(20)30815-9
doi: 10.1016/j.diabres.2020.108558
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108558

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Antonio E Pesaro (AE)

Hospital Israelita Albert Einstein, São Paulo, SP, Brazil. Electronic address: antonioepp@einstein.br.

Márcio Sommer Bittencourt (MS)

Hospital Universitario, University of Sao Paulo Medical School, Sao Paulo, Brazil.

Marcelo Franken (M)

Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.

Jose A M Carvalho (JAM)

Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.

Daniel Bernardes (D)

Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.

Jaakko Tuomilehto (J)

Finnish Institute for Health and Welfare, Helsinki, Finland; Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia.

Raul D Santos (RD)

Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; Heart Institute (InCor) University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH